Health and Healthcare

Amarin : AMRN

All Amarin Articles

63 Articles

Paul Ausick | Mar 31, 2020 at 1:17 PM EDT

Court Rejects Patent Protection, Crushing Amarin Stock

Until late Monday, Amarin continued to get good news relevant to Vascepa, its treatment for cardiovascular disease. The big news,…

Jon C. Ogg | Mar 31, 2020 at 8:56 AM EDT

Top Analyst Upgrades and Downgrades: Apache, Broadcom, Caterpillar, Dollar General, Microsoft, NXP, Salesforce, Sirius, Slack, Yelp and More

Tuesday's top analyst upgrades and downgrades included Apache, Broadcom, Caterpillar, Dollar General, Microsoft, NXP Semiconductors, Salesforce.com, Sirius XM, Slack and…

Chris Lange | Mar 18, 2020 at 11:33 AM EDT

Is Amarin Stock Poised for a Strong Recovery?

Amarin has been right in the middle of this recent market sell-off, and while shares have been halved, the stock…

Jon C. Ogg | Mar 13, 2020 at 9:10 AM EDT

Top Analyst Upgrades and Downgrades: Amazon, Adobe, AMD, Apple, BlackRock, Broadcom, Caterpillar, Deere, Microsoft, Morgan Stanley, Oracle, Slack and More

Friday's top analyst calls included Amazon, Adobe, AMD, Apple, BlackRock, Broadcom, Caterpillar, Deere, Microsoft, Morgan Stanley, Oracle and Slack.

Douglas A. McIntyre | Mar 5, 2020 at 12:40 PM EST

Amarin Stock Faces Sell-Off Crisis

Shares of Amarin have plunged in recent months. Even more troubling, there appears to no catalyst to drive them higher.

Jon C. Ogg | Feb 18, 2020 at 9:10 AM EST

Top Analyst Upgrades and Downgrades: AbbVie, Apple, Arconic, CenturyLink, eHealth, Nvidia, Salesforce, Tesla, Teva and More

Tuesday's top analyst upgrades, downgrades and initiations included AbbVie, Apple, Arconic, CenturyLink, eHealth, Nvidia, Salesforce.com, Tesla and Teva Pharmaceutical.

Douglas A. McIntyre | Feb 7, 2020 at 1:05 PM EST

When Will Amarin Stock Sell-Off Be Over?

Amarin is a development-stage biotechnology company with one FDA-approved treatment, a cardiovascular disease drug with no real competition. The company…

Jon C. Ogg | Jan 6, 2020 at 8:55 AM EST

Top Analyst Upgrades and Downgrades: Alphabet, Apple, BofA, Citigroup, Dollar Tree, Nordstrom, Salesforce, Travelers, JD.com and More

Monday's top analyst upgrades, downgrades and initiations included Alphabet, Apple, Bank of America, Citigroup, Dollar Tree, Nordstrom, Salesforce, Travelers and…

Chris Lange | Nov 29, 2019 at 10:40 AM EST

Major Biopharma Catalysts on the December FDA Calendar

Here 24/7 Wall St. includes a calendar of a few of the biggest companies expecting clinical trial and FDA updates…

Jon C. Ogg | Nov 20, 2019 at 8:55 AM EST

Top Analyst Upgrades and Downgrades: Amarin, Baker Hughes, Canopy Growth, Home Depot, Intelsat, J&J, Replimune, Schlumberger, Transocean and More

Wednesday's top analyst upgrades, downgrades and initiations include Amarin, Baker Hughes, Canopy Growth, Home Depot, Intelsat, Johnson & Johnson, Replimune,…

Jon C. Ogg | Nov 18, 2019 at 8:55 AM EST

Top Analyst Upgrades and Downgrades: Amarin, BofA, Citi, JPMorgan, Liberty SiriusXM, Microsoft, Tesla, TripAdvisor, Twitter, Workday and More

Monday's top analyst upgrades, downgrades and initiations included Amarin, Bank of America, Citigroup, JPMorgan, Liberty SiriusXM, Microsoft, Tesla, TripAdvisor, Twitter…

Jon C. Ogg | Oct 15, 2019 at 9:00 AM EDT

Top Analyst Upgrades and Downgrades: AECOM, Arconic, Bed Bath & Beyond, Dollar General, eBay, Grubhub, Lowe’s, 3M, Nvidia, Stitch Fix and More

Tuesday's top analyst upgrades, downgrades and initiations included AECOM, Arconic, Bed Bath & Beyond, Dollar General, eBay, Grubhub, Lowe's, Nvidia,…

Chris Lange | Aug 9, 2019 at 10:50 AM EDT

Is Amarin’s Cardio Trial in Trouble?

Amarin shares dropped on Friday after the firm announced that it received notice from the FDA that delays a pending…

Jon C. Ogg | Jul 17, 2019 at 6:39 PM EDT

9 After-Hours Stock Movers Tanking After Big News Reactions

24/7 Wall St. has tracked nine stocks that took big hits in the after-hours trading session on Wednesday, July 17,…

Chris Lange | Jul 2, 2019 at 10:20 AM EDT

Tuesday’s Biggest Biotech Movers

24/7 Wall St. has picked a few of those standouts from Tuesday to highlight. We have included information about each…

1 2 3 4 5

Amarin : AMRN

All Amarin Articles

Court Rejects Patent Protection, Crushing Amarin Stock

Top Analyst Upgrades and Downgrades: Apache, Broadcom, Caterpillar, Dollar General, Microsoft, NXP, Salesforce, Sirius, Slack, Yelp and More

Is Amarin Stock Poised for a Strong Recovery?

Top Analyst Upgrades and Downgrades: Amazon, Adobe, AMD, Apple, BlackRock, Broadcom, Caterpillar, Deere, Microsoft, Morgan Stanley, Oracle, Slack and More

Amarin Stock Faces Sell-Off Crisis

Top Analyst Upgrades and Downgrades: AbbVie, Apple, Arconic, CenturyLink, eHealth, Nvidia, Salesforce, Tesla, Teva and More

When Will Amarin Stock Sell-Off Be Over?

Top Analyst Upgrades and Downgrades: Alphabet, Apple, BofA, Citigroup, Dollar Tree, Nordstrom, Salesforce, Travelers, JD.com and More

Major Biopharma Catalysts on the December FDA Calendar

Top Analyst Upgrades and Downgrades: Amarin, Baker Hughes, Canopy Growth, Home Depot, Intelsat, J&J, Replimune, Schlumberger, Transocean and More

Top Analyst Upgrades and Downgrades: Amarin, BofA, Citi, JPMorgan, Liberty SiriusXM, Microsoft, Tesla, TripAdvisor, Twitter, Workday and More

Top Analyst Upgrades and Downgrades: AECOM, Arconic, Bed Bath & Beyond, Dollar General, eBay, Grubhub, Lowe’s, 3M, Nvidia, Stitch Fix and More

Is Amarin’s Cardio Trial in Trouble?

9 After-Hours Stock Movers Tanking After Big News Reactions

Tuesday’s Biggest Biotech Movers

This High-Yield ETF Combines Bond Investing With Emerging Market Currencies

SoFi Stock Could Jump 26% as Market Overreacts to One Soft Segment

China’s Semiconductor Equipment Companies Gain Share Despite U.S. Sanctions

52% of Americans Are Building Wealth While Ignoring Their Greatest Risk

3 Reasons Retirees Should Not Enroll in Medicare Advantage for 2026

This High-Yield ETF Combines Bond Investing With Emerging Market Currencies

SoFi Stock Could Jump 26% as Market Overreacts to One Soft Segment

Amarin : AMRN

All Amarin Articles

Court Rejects Patent Protection, Crushing Amarin Stock

Top Analyst Upgrades and Downgrades: Apache, Broadcom, Caterpillar, Dollar General, Microsoft, NXP, Salesforce, Sirius, Slack, Yelp and More

Is Amarin Stock Poised for a Strong Recovery?

Top Analyst Upgrades and Downgrades: Amazon, Adobe, AMD, Apple, BlackRock, Broadcom, Caterpillar, Deere, Microsoft, Morgan Stanley, Oracle, Slack and More

Amarin Stock Faces Sell-Off Crisis

Top Analyst Upgrades and Downgrades: AbbVie, Apple, Arconic, CenturyLink, eHealth, Nvidia, Salesforce, Tesla, Teva and More

When Will Amarin Stock Sell-Off Be Over?

Top Analyst Upgrades and Downgrades: Alphabet, Apple, BofA, Citigroup, Dollar Tree, Nordstrom, Salesforce, Travelers, JD.com and More

Major Biopharma Catalysts on the December FDA Calendar

Top Analyst Upgrades and Downgrades: Amarin, Baker Hughes, Canopy Growth, Home Depot, Intelsat, J&J, Replimune, Schlumberger, Transocean and More

Top Analyst Upgrades and Downgrades: Amarin, BofA, Citi, JPMorgan, Liberty SiriusXM, Microsoft, Tesla, TripAdvisor, Twitter, Workday and More

Top Analyst Upgrades and Downgrades: AECOM, Arconic, Bed Bath & Beyond, Dollar General, eBay, Grubhub, Lowe’s, 3M, Nvidia, Stitch Fix and More

Is Amarin’s Cardio Trial in Trouble?

9 After-Hours Stock Movers Tanking After Big News Reactions

Tuesday’s Biggest Biotech Movers

This High-Yield ETF Combines Bond Investing With Emerging Market Currencies

SoFi Stock Could Jump 26% as Market Overreacts to One Soft Segment

China’s Semiconductor Equipment Companies Gain Share Despite U.S. Sanctions

Featured Reads

52% of Americans Are Building Wealth While Ignoring Their Greatest Risk

3 Reasons Retirees Should Not Enroll in Medicare Advantage for 2026